Report Highlights Lower-Risk Companies with Promising Pipelines and Strong Partners

New York, September 26, 2005 – Revere Data™ LLC, a fast-growing provider of independent research data and investment analytics, today announced a newly updated Biotech Pipeline Risk Report that identifies micro- to mid-cap biotechnology companies with promising but relatively low-risk drug development pipelines.

The Biotech Pipeline Risk Report is designed to generate ideas for trading and investment opportunities in the Biopharmaceuticals sector. The updated Report is available on Revere Data’s website at http://www.reveredata.com/
research/reports/biotech/pipeline-risk2005-09.pdf

Specifically, the Biotech Pipeline Risk Report identifies companies that meet all of the following criteria:

1. At least two Phase III or FDA-filed drug candidates

2. One or more drug candidates utilizing a mechanism of action already approved by the FDA in other drugs

3. One or more drug candidates facing two or fewer alternative drugs with the same mechanism of action for the same indication

4. An established strategic partnership with at least one blue-chip biopharmaceutical company

5. Market capitalization between $50 million and $1 billion

“The 16 Biotech companies profiled in the February 17, 2005 Biotech Pipeline Risk Report provided evidence that companies meeting the stringent report requirements demonstrated less volatility than Biotech companies with only one late stage drug in their pipeline,” said Brian Hill, Director of Research for Revere Data. “5 out of the 16 featured companies had negative clinical results or FDA decisions in the past 6 months, dropping an average of 24.9%. Biotech companies dependent on single late stage drugs dropped an average of 51.9% over the same period after receiving negative results”.

“Clearly pipeline diversification is key to risk management and successful Biotech investing. Revere Data is uniquely positioned to offer unparalleled visibility into the pipeline risks and opportunities of all publicly traded Biotech companies” said Glen Wolyner, Chief Executive Officer of Revere Data.

Revere Data offers clients the flexibility to access its exclusive content through Revere Research, a user-friendly web based platform or Revere Datafeed, data files that can be integrated into research and trading applications as well as algorithms.  With either application, users gain access to Revere Data’s intelligent database of U.S publicly traded companies and ADR’s not available through other research providers. Revere Data’s clientele includes sellside agency and proprietary traders, buyside traders, hedge fund managers, portfolio managers, equity analysts, and other professionals at leading financial institutions, along with competitive intelligence, business development, and strategy specialists at major corporations.


Revere Data, LLC, provides finance and business professionals with superior data and analytics for companies traded publicly on U.S. exchanges. The Revere Data approach is based on precise product and industry classification and identification of key business relationships. Revere Data’s datafeeds and its research and real-time trading applications feature unique content derived from Revere Data’s own independent research: the Revere Hierarchy™, a patented classification system that provides unmatched detail in specifying a company’s business activities and identifying exact competitors, and Revere Relationships™, a database mapping a company to its key competitors, customers, suppliers, and strategic partners. For more information, please visit www.reveredata.com.